Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Skin Neoplasms 1Sezary Syndrome 1Sarcoma, Kaposi 1Neuroectodermal Tumors 1Neoplasms, Neuroepithelial 1Neoplasms, Nerve Tissue 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Breast Neoplasms 1AIDS-related Kaposi sarcoma 1

Interventions

pembrolizumab 24Radiotherapy 21Cisplatin 21Cetuximab 13Carboplatin 11Paclitaxel 8Nivolumab 8durvalumab 7Radiotherapy, Intensity-Modulated 6Docetaxel 6Fluorouracil 5Cyclophosphamide 5zalutumumab 4Everolimus 4Amifostine 4spartalizumab 3fludarabine 3epacadostat 3cemiplimab 3Ipilimumab 3Immune Checkpoint Inhibitors 3Gefitinib 3Filgrastim 3Erlotinib Hydrochloride 3Celecoxib 3Capecitabine 3selpercatinib 2palbociclib 2fludarabine phosphate 2bintrafusp alfa protein, human 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Head and Neck Neoplasms × Interleukin-12 × Clear all
NCT00004070 2017-04-20

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

Dana-Farber Cancer Institute

Phase 1/2 Completed
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡